share_log

Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $20

Benzinga ·  Mar 17 11:48

Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lowers the price target from $32 to $20.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 405

Recommended

Write a comment